Phase II, Dose-Escalation Study of Pacritinib (SB1518), a novel JAK2-FLT3 inhibitor, with and without combination of 5-Azacytidine, in patients with FLT3-mutated Acute Myeloid Leukemia (AML)

Trial Profile

Phase II, Dose-Escalation Study of Pacritinib (SB1518), a novel JAK2-FLT3 inhibitor, with and without combination of 5-Azacytidine, in patients with FLT3-mutated Acute Myeloid Leukemia (AML)

Discontinued
Phase of Trial: Phase II

Latest Information Update: 29 May 2014

At a glance

  • Drugs Pacritinib (Primary) ; Azacitidine
  • Indications Acute myeloid leukaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 29 May 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top